Diligence memo · auto-generated · as of July 2, 2026
Lyell Immunopharma, Inc.
Lyell Immunopharma, Inc. has raised $493M over 1 round; too few niche peers to rank its valuation yet.
Businessfiled
Lyell Immunopharma, Inc. operates in Pharmaceuticals, based in SOUTH SAN FRANCISCO.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Lyell Immunopharma, Inc. has raised $493M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Growth/Late (a round over $400M).
Largest single filing: $493M on 2020-03-05.
Most recent recorded round closed around 2020-03-05.
Valuation (modeled)modeled
Provath models Lyell Immunopharma, Inc. at approximately $17.9B (range $3.2B–$32.3B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Too few comparable companies in this niche to rank the valuation fairly yet.
Financing rhythm & timingmixed
Last raise 6.3 yr ago; this sector typically re-raises about every 13 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 99% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 100% of those peers.
Closest niche peers: Catalent, Inc., Sage Therapeutics, Inc..
Peoplefiled
11 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.